Amy C. Moore, Director of Patient Engagement and Advocacy at Summit Therapeutics, shared a post on LinkedIn about a paper by Hongbin Ji et al. published in Nature Communications:
“For the past several years, I have been part of Cancer Grand Challenges Team CANCAN, working to understand the drivers of and find new treatments for cancer cachexia.
This new paper looks at the role of the PIK3CA gene in promoting cachexia in patients with EGFR+ NSCLC.”
Title: Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer
Authors: Meiting Yue, Zhen Qin, Shijie Tang, Xinlei Cai, Yikai Zhao, Chen Yang, Liang Chen, Luonan Chen and Hongbin Ji
You can read the full article in Nature Communications.
You can also read the article: FDA Approves RYBREVANT FASPRO as the First Subcutaneous Amivantamab Option for EGFR-Mutated NSCLC
